Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla: Margins disappoint again - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jan 21, 2002

    Cipla: Margins disappoint again

    Pharma major, Cipla has declared encouraging sales growth of 33% for 3QFY02 which is more or less in line with the street's expectations. However, a sharp slide in operating margins has come as a major disappointment from the company.

    (Rs m) 3QFY01 3QFY02 Change
    Sales 2,756 3,663 32.9%
    Other Income 82 153 86.9%
    Expenditure 2,070 2,942 42.2%
    Operating Profit (EBDIT) 687 720 4.9%
    Operating Profit Margin (%) 24.9% 19.7%  
    Interest 3 8 169.0%
    Depreciation 40 49 21.3%
    Profit before Tax 725 817 12.6%
    Other Adjustments - -  
    Tax 190 190 0.0%
    Profit after Tax/(Loss) 535 627 17.0%
    Net profit margin (%) 19.4% 17.1%  
    No. of Shares (eoy) (m) 60.0 60.0  
    Diluted Earnings per share 35.7 41.8  
    P/E (at current price) 28  

    Though we were expecting a drop in margins, a 520 basis points slide comes as a surprise especially with increasing contribution from export revenues. This is third quarter in a row, that Cipla has recorded a drop in operating margins. The drop seems to be on the back of rising marketing expenses.

    3QFY02: Projected vs. Actuals
    Particulars Actuals Projected % Change
    Total Sales (Rs. m) 3663 3,608 1.52%
    Operating Profit 720 779 -7.61%
    Operating Margins (%) 19.7 21.6 NA
    Net Profit (Rs. m) 627 671 25.40%

    Exports seem to have recorded a healthy growth of 75-80% in line with our expectations. Domestic sales also seem to have grown in line with expectations (13-14%). The company has already started exporting bulk Omeprazole to Andrx. Considering the fact that generic launch by Andrx is expected only in June’02, it is expected to stock up 4-5 months ahead of its launch. The fourth quarter of the current year should see considerable revenue contribution from export of Omeprazole bulk by Cipla. We are expecting Omeprazole export revenues of Rs 677 m (US$ 14 m) in the current year. There is still uncertainty with regard to timing of exports of CFC free inhalers to European and anti-AIDS drugs to the South African markets.

    Though insignificant on the net basis, interest burden has gone up sharply in last couple of quarters. This could be due to borrowings by the company for setting up its new formulations plant in Goa at a cost of Rs 1.2 bn. Depreciation expenses also seem to have gone up on that account. However, the company is expected to save on tax outgo due to commencement of the new Goa plant.

    At the current market price of Rs 1,168, the stock trades at a P/e of 28 x annualised earnings. Considering a sharp fall in operating margins, we would be revising our earnings estimates downwards. The stock might see selling pressure due to initial disappointment.



    Equitymaster requests your view! Post a comment on "Cipla: Margins disappoint again". Click here!


    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 16, 2017 (Close)



    Detailed Quarterly Results With Charts